“We’re pleased to present mechanistic data demonstrating the effectiveness of plinabulin for the prevention of chemotherapy-induced neutropenia (CIN). The acceptance of this data by ESMO provides continued validation of our CIN program and how plinabulin can complement the current standard of care,” said Dr.
Poster Presentation Details
Title: Clinical Evaluation of Plinabulin’s Granulocyte-Monocyte Progenitor (GMP) Stem Cell Effects for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
Presentation #: 1588P
Presenter: Dr.
- Peripheral blood counts for mature (segmented) and immature neutrophils, white blood cells (WBCs), red blood cells (RBCs) and platelets were obtained from LabCorp. The blood counts were analyzed before and 24 hours after chemo administration without (control; N=198) or with plinabulin (N=298).
- The absolute neutrophil count (ANC) with and without plinabulin was comparable at pre-dose C1D1 (p=0.96) but was significantly higher at 24 hours post-chemo dose with plinabulin vs. control (p<0.0001). At 24 hours post-chemo dose, the mean ANC had increased by 3.2 x 109/L with plinabulin (p<0.0001) whereas the mean ANC had decreased by 0.55 x 109/L with the control (p=0.018) due to the myelosuppressive effect of TAC chemotherapy.
- Pre-dose (C1D1), the proportion of patients with a GMP-derived immature cell count value >0 was ~0 for both the plinabulin and control arms. At 24 hours post-chemo, the number of patients with an immature neutrophil count >0 had significantly increased with plinabulin but not with the control (shown in the table below). The proportion of patients with immature cells from all other WBCs and RBCs was ~0 at pre- or post-chemo dose with or without plinabulin.
Proportion of patients with these GMP-derived immature cells: | Pre-dose C1D1 plinabulin N (%) | Pre-dose C1D1 control N (%) | p-value | 24 hours post-plinabulin N (%) | 24 hours post-control N (%) | p-value |
Promyelocytes | 0 (0) | 0 (0) | NA | 2 (0.7) | 0 (0) | 0.25 |
Myelocytes | 1 (0.4) | 1 (0.5) | 0.8 | 23 (7.7) | 0 (0) | <0.0001 |
Metamyelocytes | 1 (0.4) | 1 (0.5) | 0.8 | 20 (6.7) | 0 (0) | 0.0002 |
Bands | 11 (3.7) | 9 (4.5) | 0.6 | 21 (7.0) | 2 (1.0) | 0.0017 |
Dr.
About Plinabulin
Plinabulin, BeyondSpring’s lead asset, is a selective immunomodulating microtubule-binding agent, which is a potent antigen presenting cell (APC) inducer that is being developed as an anticancer agent. Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anti-cancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells and the second is a CIN prevention benefit. Plinabulin has single agent anti-cancer activity in a number of cancers including small cell lung cancer (SCLC) and multiple myeloma (MM). Plinabulin also exerts early-onset of action in the prevention of chemotherapy-induced neutropenia (CIN) by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
About
Headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet the Company’s expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the
Investor Contact:
+1 617-430-7577
arr@lifesciadvisors.com
Media Contact:
+1 646-627-8387
darren@lifescicomms.com
Source:
2022 GlobeNewswire, Inc., source